产品说明书

LP-533401 HCl

Print
Chemical Structure| 1040526-12-2 同义名 : LP-533401 hydrochloride
CAS号 : 1040526-12-2
货号 : A658929
分子式 : C27H23ClF4N4O3
纯度 : 97%
分子量 : 562.943
MDL号 : MFCD18803629
存储条件:

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(44.41 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Tryptophan hydroxylase 1 (Tph1) is the initial enzyme in the biosynthesis of gut-derived serotonin. LP-533401 HCl inhibits human Tph1 in vitro with an IC50 value of 0.7 μM. It also blocked the activity of purified recombinant human Tph2 with similar potency. In rat mastocytoma RBL2H3 cells that endogenously express Tph1, LP-533401 inhibited serotonin production with an IC50 value of 0.4 μM[2]. The complete inhibition on serotonin production in Tph1-expressing cells was found at the concentration of 1 μM[3]. In ovariectomized female C57Bl6/J mice, administration of LP-533401 (10 – 250 mg/kg/day) for 28 days significantly increased the bone mass, as well as the bone formation parameters, such as osteoblast numbers, bone formation rate, and osteocalcin serum levels when compared to vehicle-treated controls. LP-533401 treatment also dose-dependently decreased the level of serotonin in serum, whereas the brain serotonin content remained unaltered[3].
作用机制 LP-533401 HCl inhibits Tph1 activity by interacting with the two amino acids, Tyr235 and Phe241, near Tph1 catalytic site.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.88mL

1.78mL

0.89mL

17.76mL

3.55mL

1.78mL

参考文献

[2]Liu Q, Yang Q, Sun W, Vogel P, Heydorn W, Yu XQ, Hu Z, Yu W, Jonas B, Pineda R, Calderon-Gay V, Germann M, O'Neill E, Brommage R, Cullinan E, Platt K, Wilson A, Powell D, Sands A, Zambrowicz B, Shi ZC. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther. 2008 Apr;325(1):47-55. doi: 10.1124/jpet.107.132670. Epub 2008 Jan 11. PMID: 18192499.

[3]Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010 Mar;16(3):308-12. doi: 10.1038/nm.2098. Epub 2010 Feb 7. PMID: 20139991; PMCID: PMC2836724.